Immunome director-linked entity sells 100K shares

Immunome Inc. director Isaac Barchas reported that an entity associated with him, AMBHMC II LLC, sold a total of 100,000 shares of Immunome common stock in open-market transactions under a pre-arranged Rule 10b5-1 trading plan adopted on March 31, 2026.

Rhea-AI Filing Summary

Immunome Inc. director Isaac Barchas reported that an entity associated with him, AMBHMC II LLC, sold a total of 100,000 shares of Immunome common stock in open-market transactions under a pre-arranged Rule 10b5-1 trading plan adopted on March 31, 2026.

The sales occurred on July 6 and July 7, 2026, at weighted average prices of about $24.11 and $24.20 per share across specified price ranges. After these transactions, filings show 108,504 shares held indirectly and 103,259 shares held directly. Barchas disclaims beneficial ownership of the LLC-held shares beyond any pecuniary interest.

Insider Trade Summary 10b5-1

Net Seller: 100,000 shares

Net Sell 3 txns

Insider Barchas Isaac

Role Director

Sold 100,000 shs ($2.41M)

Type	Security	Shares	Price	Value
Sale	Common Stock	16,906	$24.20	$409K
Sale	Common Stock	83,094	$24.11	$2.00M
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 108,504 shares (Indirect, See footnote); Common Stock — 103,259 shares (Direct)

Footnotes (4)

1. F1. The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by AMBHMC II LLC ("ABHMC") on March 31, 2026.
2. F2. The weighted average sale price for the transaction report was $24.11, and the range of prices were between $24.00 and $24.29, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
3. F3. ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.
4. F4. The weighted average sale price for the transaction report was $24.20, and the range of prices were between $24.00 and $24.58, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Key Figures

Total shares sold: 100,000 shares Sale on July 6, 2026: 83,094 shares at $24.11 weighted average Sale on July 7, 2026: 16,906 shares at $24.20 weighted average +2 more

5 metrics

Total shares sold 100,000 shares Open-market sales reported in Form 4

Sale on July 6, 2026 83,094 shares at $24.11 weighted average AMBHMC II LLC open-market sale

Sale on July 7, 2026 16,906 shares at $24.20 weighted average AMBHMC II LLC open-market sale

Indirect holdings after transactions 108,504 shares Shares reported as held indirectly post-sale

Direct holdings after transactions 103,259 shares Shares reported as held directly on July 6, 2026

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, beneficial ownership, pecuniary interest

4 terms

Rule 10b5-1 trading plan regulatory

"The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by AMBHMC II LLC"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"The weighted average sale price for the transaction report was $24.11"

beneficial ownership regulatory

"The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

pecuniary interest financial

"except to the extent of his pecuniary interest in such shares, if any"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider activity did Immunome (IMNM) report in this Form 4?

Immunome reported that an entity associated with director Isaac Barchas, AMBHMC II LLC, sold 100,000 shares of common stock in open-market transactions. The trades were executed under a Rule 10b5-1 trading plan and spanned July 6 and July 7, 2026, at prices around $24 per share.

How many Immunome (IMNM) shares were sold and at what prices?

AMBHMC II LLC sold 100,000 Immunome common shares in total. One block of 83,094 shares had a weighted average price of $24.11, and another block of 16,906 shares had a weighted average price of $24.20, within disclosed intraday price ranges around those levels.

Was the Immunome (IMNM) insider sale made under a Rule 10b5-1 plan?

Yes. The filing states the reported sales occurred automatically under a Rule 10b5-1 trading plan adopted by AMBHMC II LLC on March 31, 2026. Such plans pre-schedule trades, indicating the timing of these July 2026 sales was established in advance rather than decided spontaneously.

Who actually owns the Immunome (IMNM) shares involved in the reported sale?

The filing explains that AMBHMC II LLC owns the Immunome common stock sold, while director Isaac Barchas is a managing member with power of attorney. Barchas disclaims beneficial ownership of those shares except to the extent of his pecuniary interest, if any, in the LLC-held position.

How many Immunome (IMNM) shares does the insider report holding after the sale?

After the reported transactions, filings show 108,504 Immunome shares held indirectly and 103,259 shares held directly. These figures indicate that, despite the 100,000-share sale by AMBHMC II LLC, a substantial combined position in Immunome common stock remains associated with the reporting person.

What price ranges did the Immunome (IMNM) insider sales cover?

For the 83,094-share sale, the weighted average price was $24.11 within a $24.00 to $24.29 range. For the 16,906-share sale, the weighted average price was $24.20 within a $24.00 to $24.58 range. Detailed execution prices are available on request to the issuer or SEC staff.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/07/2026 - 07:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Barchas Isaac

(Last) (First) (Middle)

C/O IMMUNOME, INC.

18702 N. CREEK PARKWAY, SUITE 100

(Street)

BOTHELL WASHINGTON 98011

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Immunome Inc. [ IMNM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/06/2026		S(1)		83,094	D	$24.11(2)	125,410	I	See footnote(3)
Common Stock	07/07/2026		S(1)		16,906	D	$24.2(4)	108,504	I	See footnote(3)
Common Stock								103,259	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by AMBHMC II LLC ("ABHMC") on March 31, 2026.

2. The weighted average sale price for the transaction report was $24.11, and the range of prices were between $24.00 and $24.29, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

3. ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.

4. The weighted average sale price for the transaction report was $24.20, and the range of prices were between $24.00 and $24.58, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

	/s/ Sandra Stoneman, Attorney-in-Fact	07/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)